This quarter, Galapagos inked a mega-deal with Gilead Sciences for the development and commercialization of filgotinib and other pipeline molecules.
With the strong phase 3 FINCH data, Gilead is submitting filgotinib for approval in the U.S. for rheumatoid arthritis by year-end. I expect approval in 2H2020.
The overall pipeline advancement is progressing at a rapid pace. As such, I anticipate more appreciation from this low-risk growth equity.
Does the company have products or services with sufficient market potential to make possible a sizable increase in sales for at least several years? - Philip Fisher
If you've been following my work, you'd noticed